The Quality Lowdown: Key Inspection Findings At Glenmark, Centrient, Lupin, Aurobindo, Mac-Chem

US and EU drug GMP inspections at API and drug product manufacturing sites in India found fault with investigations, process validation, data integrity and contamination prevention.

The Quality Lowdown

Inadequate investigations were a major focus of recent drug GMP inspections by the US Food and Drug Administration and EU national authorities that resulted in serious findings, with consequences so far of two FDA warning letters and two EU good manufacturing practices noncompliance notices.

Other key focus areas: process validation, data integrity and contamination.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Manufacturing

More from Compliance